The London Life Sciences team advised Quanta Dialysis Technologies on the successful first closing of its Series C funding round, raising £38 million ($48 million). The round was led by a Swiss private family office in combination with btov Partners and co-led by Wellington Partners and Seroba Life Sciences, along with participation from other existing investors. Proceeds will be used to fund the UK commercial launch of SC+ and a 510(k) submission to the FDA later this year.
Founded in 2008, Quanta Dialysis Technologies’ mission is to improve the lives of dialysis patients through innovation. The company’s lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK.
For additional details on the funding round, please read the press release.